AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Tmunity Announces Participation at Four Upcoming Investor Conferences

March 1, 2019

PHILADELPHIA--(BUSINESS WIRE)--Mar 1, 2019--Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at four investor conferences in March 2019.

  • Cowen and Company 39th Annual Health Care Conference
    Monday, March 11, 2019
    Podium presentation at 12:00 p.m. ET
    Boston, MA
  • Barclays Global Health Care Conference
    Tuesday, March 12, 2019
    Miami Beach, FL
  • Oppenheimer’s 29th Annual Health Care Conference
    Thursday, March 19, 2019
    New York, NY
  • William Blair 9th Annual Cancer Immunotherapy Conference
    Wednesday, March 20, 2019
    Podium presentation at 9:25 a.m. ET
    New York, NY

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190301005024/en/

CONTACT: Investors:

Graeme Bell

Chief Financial Officer

ir@tmunity.com

215-966-1600Media:

Mike Beyer, Sam Brown Inc.

mikebeyer@sambrown.com

312-961-2502

KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS NEW YORK PENNSYLVANIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Tmunity Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 03/01/2019 08:00 AM/DISC: 03/01/2019 08:01 AM

http://www.businesswire.com/news/home/20190301005024/en